SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Frödin Jan Erik)
 

Sökning: WFRF:(Frödin Jan Erik) > Clinical Phase I st...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003747naa a2200421 4500
001oai:DiVA.org:uu-129608
003SwePub
008100819s2011 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:122176301
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1296082 URI
0247 a https://doi.org/10.3109/0284186X.2010.4993702 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1221763012 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ekman, Simonu Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)simoekma
2451 0a Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor :b Experiences in patients with squamous non-small cell lung carcinoma
264 1c 2011
338 a print2 rdacarrier
520 a Background. Inhibition of the Insulin-like Growth Factor-1 receptor (IGF-1R) has resulted in extensive anti-tumor effects. Picropdophyllin (PPP, AXL1717) is a small-molecule inhibitor of the IGF-1R without inhibition of closely related receptors including the insulin receptor and has shown extensive effects against a wide range of tumors in animals. PPP is currently tested as an orally administrated single agent treatment in an open-label combined Phase I/II clinical study in advanced cancer patients with solid tumors which progress in spite of several lines of treatment. Patients and methods. The first part (Phase IA) consisted of single day BID dosing every three weeks with consecutive dose escalations. The second part (Phase IB) consists of seven days or longer BID dosing every three weeks, dosing range being 520-700 mg BID. Non-progressing patients could continue treatment within a compassionate use setting. Results and discussion. The present report describes our experience with the four patients with progressive squamous non-small cell lung cancer (NSCLC) that have received treatment with PPP. Despite more than seven months of PPP treatment as third or fourth line treatment, the reported patients did not develop any additional metastases. Furthermore, CT scans as well as (18)FDG-Positron Emission Tomography (PET) scans of the patients demonstrated large central necrotic areas, which may suggest tumor response. At the same time, the study drug is so far well tolerated. The phenomenon of necrosis in the tumors suggestive of tumor response has not been reported before in anti-IGF-1R treatment and will be subject to further studies in the present clinical trial.
653 a MEDICINE
653 a MEDICIN
7001 a Frödin, Jan-Eriku Karolinska Institutet4 aut
7001 a Harmenberg, Johan4 aut
7001 a Bergman, Antoninau Uppsala universitet,Enheten för radiologi4 aut0 (Swepub:uu)abe03125
7001 a Hedlund, Åsau Uppsala universitet,Enheten för onkologi4 aut
7001 a Dahg, Piau Uppsala universitet,Enheten för onkologi4 aut
7001 a Alvfors, Carinau Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)carialvf
7001 a Ståhl, Birgitta4 aut
7001 a Bergström, Stefanu Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)stebe792
7001 a Bergqvist, Michaelu Uppsala universitet,Enheten för onkologi4 aut0 (Swepub:uu)michberg
7102 a Uppsala universitetb Enheten för onkologi4 org
7730 t Acta Oncologicag 50:3, s. 441-447q 50:3<441-447x 0284-186Xx 1651-226X
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-129608
8564 8u https://doi.org/10.3109/0284186X.2010.499370
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:122176301

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy